Baker IDI Heart and Diabetes Institute, Melbourne, Australia.
Pathology. 2012 Feb;44(2):110-4. doi: 10.1097/PAT.0b013e32834e8e12.
The prevalence of type 2 diabetes is rapidly increasing. A strong rationale exists for identifying asymptomatic individuals who are at high risk or are likely to have diabetes. Screening programs may provide a conduit through which diabetes intervention may be targeted towards those who might benefit most. Diabetes screening could lessen disease burden in two ways. Firstly, by identifying people with undiagnosed diabetes, the burden of diabetes complications could be lessened through appropriate management of the condition. Secondly, by indentifying people at high risk of developing diabetes, and entering these people into diabetes prevention programs, the number of people with diabetes could be reduced. Screening for diabetes should ideally involve a non-invasive risk assessment followed by blood testing for those found to be at high risk. It should be noted that conclusive randomised controlled trial data to support the long-term health and economic impact of screening programs is lacking. The answers surrounding who and how we should screen for diabetes and the associated long term benefits will continue to evolve as the evidence base builds. As the use of screening for diabetes builds in popularity, it is essential that health care systems are sufficiently equipped to effectively manage the newly identified high risk and prevalent cases of type 2 diabetes.
2 型糖尿病的患病率正在迅速上升。有充分的理由确定无症状的高危人群或可能患有糖尿病的人群。筛查项目可以为糖尿病干预提供一个渠道,使那些可能受益最大的人群得到针对性的治疗。糖尿病筛查可以通过两种方式减轻疾病负担。首先,通过发现未确诊的糖尿病患者,可以通过适当的疾病管理来减轻糖尿病并发症的负担。其次,通过发现有发展为糖尿病风险的高风险人群,并将这些人纳入糖尿病预防计划,可以减少糖尿病患者的数量。糖尿病筛查理想情况下应包括非侵入性风险评估,然后对高风险人群进行血液检测。值得注意的是,缺乏支持筛查计划对长期健康和经济影响的结论性随机对照试验数据。随着证据基础的建立,关于我们应该筛查谁以及如何筛查糖尿病以及相关的长期益处的答案将继续发展。随着糖尿病筛查的普及,医疗保健系统必须具备足够的能力,有效地管理新发现的 2 型糖尿病高危和普遍病例。